Michelle Xia on Akeso's Rapid Expansion and Groundbreaking Drug Development | Michelle Xia, CEO, Akeso Inc. 00:10:00
Michelle Xia, Ph.D., CEO of Akeso, joins the Business of Biotech to discuss the company's remarkable growth and its impressive portfolio. Akeso boasts 20 drug development programs, including 12 clinical-stage antibodies, six bi-specific antibodies (two in clinical stages), and four FDA-approved IND antibodies. With 22 initiated clinical trials, Xia sheds light on how Akeso has achieved such extraordinary progress and what the future holds for this trailblazing biopharmaceutical company.
